Literature DB >> 22668877

Twist1 causes the transcriptional repression of claudin-4 with prognostic significance in esophageal cancer.

Keun-Woo Lee1, Nam Kyung Lee, Jeong Hoon Kim, Myung Soo Kang, Hae Yong Yoo, Hyeon Ho Kim, Sung Hee Um, Seok-Hyung Kim.   

Abstract

Twist1 is a transcription factor that is involved in epithelial-mesenchymal transition by suppressing intercellular adhesion. In this study, we aimed to determine the role of Twist1 in the regulation of claudin-4 expression and investigate its specific mechanisms and clinical implications using human esophageal carcinoma cell lines and tissues. As a result, up-regulation of Twist1 decreased both gene and protein expression levels of endogenous claudin-4 and the suppression was mediated by direct binding of Twist1 to the canonical E-box in the promoter region of claudin-4. In addition, there was a significant inverse correlation of claudin-4 with Twist1 in esophageal cancer tissues. High Twist1 and low claudin-4 expression was associated with the poorest prognosis and was more highly correlated with adverse outcome than any other subgroup with statistical significance (p=0.001). Our results indicate that Twist1 induces the repression of claudin-4 expression during the epithelial-mesenchymal transition in esophageal carcinoma.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22668877     DOI: 10.1016/j.bbrc.2012.05.140

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Decreased expression of claudin-3 is associated with a poor prognosis and EMT in completely resected squamous cell lung carcinoma.

Authors:  Juanjuan Che; Yifan Yang; Jing Xiao; Pengfei Zhao; Bo Yan; Shuo Dong; Bangwei Cao
Journal:  Tumour Biol       Date:  2015-03-28

2.  Vaccine-mediated immunotherapy directed against a transcription factor driving the metastatic process.

Authors:  Andressa Ardiani; Sofia R Gameiro; Claudia Palena; Duane H Hamilton; Anna Kwilas; Thomas H King; Jeffrey Schlom; James W Hodge
Journal:  Cancer Res       Date:  2014-02-11       Impact factor: 12.701

3.  Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases.

Authors:  Xiying Shang; Xinjian Lin; Edwin Alvarez; Gerald Manorek; Stephen B Howell
Journal:  Neoplasia       Date:  2012-10       Impact factor: 5.715

Review 4.  Twist: a molecular target in cancer therapeutics.

Authors:  Md Asaduzzaman Khan; Han-chun Chen; Dianzheng Zhang; Junjiang Fu
Journal:  Tumour Biol       Date:  2013-07-20

Review 5.  Genes Regulating Epithelial Polarity Are Critical Suppressors of Esophageal Oncogenesis.

Authors:  Xiu-Min Li; Hui Wang; Li-Li Zhu; Run-Zhen Zhao; Hong-Long Ji
Journal:  J Cancer       Date:  2015-06-11       Impact factor: 4.207

Review 6.  Emerging roles of claudins in human cancer.

Authors:  Mi Jeong Kwon
Journal:  Int J Mol Sci       Date:  2013-09-04       Impact factor: 5.923

7.  Twist1 Influences the Expression of Leading Members of the IL-17 Signaling Pathway in HER2-Positive Breast Cancer Cells.

Authors:  Bruno R B Pires; Renata Binato; Gerson M Ferreira; Stephany Corrêa; Bárbara Du Rocher; Daniel Bulzico; Susanne Crocamo; Everton Cruz Dos Santos; Luize G Lima; Eliana Abdelhay
Journal:  Int J Mol Sci       Date:  2021-11-10       Impact factor: 5.923

Review 8.  Intestinal Barrier, Claudins and Mycotoxins.

Authors:  Marta Justyna Kozieł; Maksymilian Ziaja; Agnieszka Wanda Piastowska-Ciesielska
Journal:  Toxins (Basel)       Date:  2021-10-26       Impact factor: 4.546

Review 9.  Claudins overexpression in ovarian cancer: potential targets for Clostridium Perfringens Enterotoxin (CPE) based diagnosis and therapy.

Authors:  Diana P English; Alessandro D Santin
Journal:  Int J Mol Sci       Date:  2013-05-17       Impact factor: 5.923

10.  Role of grainyhead-like 2 in the formation of functional tight junctions.

Authors:  Naoki Tanimizu; Toshihiro Mitaka
Journal:  Tissue Barriers       Date:  2013-01-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.